A Phase I Study of SUNITINIB and Rapamycin in Advanced Non-Small Cell Lung Cancer (NSCLC)
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
To define the optimal dose of sunitinib when given in combination with rapamycin 2mg.
To determine the maximum tolerated dosage of sunitinib and rapamycin given in this fashion.
To determine the how many times and how severe other toxicities of this combination therapy.
To determine how quickly the patient(s) will respond the the drug, overall survival and time
to progression for this combination therapy.